LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Home・Elenco Azioni・Editas Medicine Inc

Editas Medicine Inc

Chiusa

SettoreSettore sanitario

1.5 7.91

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.33

Massimo

1.5

Metriche Chiave
By Trading Economics
Entrata	-31M -76M
Vendite	-26M 4.7M
EPS	-0.55
Margine di Profitto	-1,633.491
Dipendenti	246
EBITDA	28M -33M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+125.36% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2025

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-17M 129M
Apertura precedente	-6.41
Chiusura precedente	1.5

Notizie sul Sentiment di mercato

By Acuity

37%

63%

124 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

1.33 / 1.54 Supporto e resistenza

Editas Medicine Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

15 mag 2025, 22:52 UTC

Utili

I principali Market Mover

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15 mag 2025, 20:37 UTC

Notizie principali

Utili

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16 mag 2025, 00:00 UTC

Discorsi di Mercato

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15 mag 2025, 23:47 UTC

Discorsi di Mercato

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15 mag 2025, 23:38 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

15 mag 2025, 23:38 UTC

Discorsi di Mercato

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15 mag 2025, 23:14 UTC

Notizie principali

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15 mag 2025, 22:46 UTC

Notizie principali

Acquisizioni, Fusioni, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mag 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15 mag 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15 mag 2025, 22:46 UTC

Acquisizioni, Fusioni, Takeovers

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15 mag 2025, 21:58 UTC

Utili

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15 mag 2025, 21:24 UTC

Utili

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15 mag 2025, 20:56 UTC

Discorsi di Mercato

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15 mag 2025, 20:54 UTC

Discorsi di Mercato

Utili

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15 mag 2025, 20:54 UTC

Utili

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15 mag 2025, 20:51 UTC

Utili

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15 mag 2025, 20:50 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

15 mag 2025, 20:50 UTC

Acquisizioni, Fusioni, Takeovers

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15 mag 2025, 20:50 UTC

Utili

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15 mag 2025, 20:47 UTC

Utili

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15 mag 2025, 20:47 UTC

Utili

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15 mag 2025, 20:47 UTC

Utili

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15 mag 2025, 20:47 UTC

Utili

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15 mag 2025, 20:37 UTC

Utili

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15 mag 2025, 20:37 UTC

Utili

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15 mag 2025, 20:37 UTC

Utili

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15 mag 2025, 20:37 UTC

Utili

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15 mag 2025, 20:26 UTC

Notizie principali

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15 mag 2025, 20:25 UTC

Utili

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Editas Medicine Inc Previsione

Obiettivo di Prezzo

By TipRanks

125.36% in crescita

Previsioni per 12 mesi

Media 3.11 USD 125.36%

Alto 5 USD

Basso 1 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Editas Medicine Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Editas Medicine Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

1.33 / 1.54Supporto e resistenza

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Sentiment

By Acuity

124 / 382 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.